Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks

PR Newswire

VANCOUVER, BC, Jan. 27, 2026

Issued on behalf of Oncolytics Biotech Inc.

(NASDAQ: CHRS) at the intersection of pivotal execution readiness and combination immunotherapy innovation in high-unmet-need gastrointestinal and respiratory cancer markets.FDA'sOncolytics Biotech Inc.ModernaMerckVir BiotechnologyCoherus OncologyEquity-Insider.comNews CommentaryVANCOUVER, BCJan. 27, 2026^[1]^[2]

As pharmaceutical giants face a staggering patent cliff, they are aggressively hunting for late-stage assets with clear, high-signal registration pathways^[3]^[4]

(NASDAQ: ONCY) is strengthening its operational and clinical leadership as it advances pelareorep toward multiple registration-directed programs in gastrointestinal cancers.Oncolytics Biotech Inc.

The companyrecently announcedCG OncologyMorphic TherapeuticEli LillyTakeda

"John's background running complex, late-stage oncology trials makes him exceptionally well-suited to leadOncolytics'Oncolytics Biotech

These appointments complete a transformative executive team buildout following Kelly'spromotion to CEO addition $2 billion acquisition expanded its Scientific Advisory BoardAmbrx Biopharma'sJohnson & JohnsonOncolyticsMemorial Sloan Kettering Cancer CenterMD Anderson Cancer Center

The company recentlyannounced breakthrough efficacy data

The company is also advancing pelareorep toward potential accelerated approval in anal cancer after reporting third-line data that achieved a29% objective response rate

Second-line or later results were equally compelling, with pelareorep achieving a30% response rate

on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this disease. This regulatory milestone clears the path for initiating a pivotal study in one of oncology's most challenging therapeutic areas.secured FDA alignmentOncolytics

https://equity-insider.com/2025/03/18/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/CONTINUED… Read this and more news for Oncolytics Biotech at:

In other recent industry developments and happenings in the market include:

alone in patients with high-risk stage III/IV melanoma following complete resection.announcedModernaMerckKEYTRUDAKEYTRUDA

"Now with five years of follow-up data, today's results highlight the potential of a prolonged benefit of the intismeran autogene andKEYTRUDAModerna

The companies have eight Phase 2 and Phase 3 clinical trials underway across multiple tumor types, including melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma.ModernaMerck

dual-masked T-cell engager VIR-5500 in prostate cancer to be presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium in February. VIR-5500 is currently being evaluated as monotherapy and in combination with androgen receptor pathway inhibitors for the first-line treatment of metastatic castration-resistant prostate cancer, with the Phase 1 trial successfully clearing the second dose cohort.provided updatesVir BiotechnologyPRO-XTEN

The Company is also currently enrolling patients in its Phase 1 dose escalation trials for VIR-5818 in HER2-expressing solid tumors and VIR-5525 in EGFR-expressing solid tumors, with Phase 1 dose escalation response data for VIR-5818 expected in the second half of 2026.Vir BiotechnologyPRO-XTENPRO-XTEN

in Molecular Cancer Therapeutics highlighting the strong pharmacology of investigational CCR8 antibody tagmokitug, demonstrating picomolar binding affinity with no off-target binding. The publication provides important scientific evidence showing tagmokitug selectively eliminates CCR8+ T regulatory cells without affecting other immune cells, with proof-of-mechanism established in first-in-human clinical studies showing selective reductions in CCR8+ Tregs.announced publicationCoherus Oncology

"This publication presents the robust pharmacology of tagmokitug in preclinical and clinical studies, and with a selectivity profile and potent binding and killing of CCR8+ T regulatory cells and not other immune cells. These data provide evidence that tagmokitug has the potential for a differentiated profile," said Theresa LaVallee, Ph.D., Chief Scientific and Development Officer atCoherus

is currently evaluating tagmokitug in Phase 1b/2a clinical trials in patients with solid tumors, including head and neck, colorectal, gastric, and esophageal cancer. The company's immunotherapy pipeline focuses on enhancing innate and adaptive immune responses to enable robust antitumor activity in combination with the approved PD-1 inhibitor LOQTORZI.Coherus Oncology

https://equity-insider.com/2025/03/18/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/Source:

CONTACT:

Equity Insider

info@equity-insider.com

(604) 265-2873

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.DISCLAIMER:

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

SOURCES:

Logo -https://mma.prnewswire.com/media/2840019/5737560/Equity_Insider_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/registration-ready-how-2026s-clinical-leaders-are-beating-cancer-benchmarks-302671414.html